Eli Casdin - Feb 20, 2024 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Signature
/s/ Eli Cadin by Agnieszka Gallagher, Attoney-in-Fact
Stock symbol
LAB
Transactions as of
Feb 20, 2024
Transactions value $
$57,000
Form type
4
Date filed
2/22/2024, 05:01 PM
Previous filing
Jan 9, 2024
Next filing
Jun 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock Award $57K +22.8K +28.23% $2.50 104K Feb 20, 2024 Direct F1, F2
holding LAB Common Stock 7.55M Feb 20, 2024 By CMLS Holdings II LLC F3
holding LAB Common Stock 11.2M Feb 20, 2024 By Cadin Partners Master Fund, L.P. F4
holding LAB Common Stock 2.74M Feb 20, 2024 By Casdin Private Growth Equity Fund, L.P. F5
holding LAB Common Stock 1.2M Feb 20, 2024 See Footnote F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units that vest in four equal quarterly installments beginning on March 15, 2024. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control.
F2 The Restricted Stock Units were issued to the Reporting Person, who elected to take Restricted Stock Units in lieu of $57,000 in cash compensation for services as a board member.
F3 The shares are held of record by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Mr. Casdin, who, as a member of the Board of Managers of CMLS Holdings III, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II. Mr. Casdin may be deemed to have or share beneficial ownership of the securities held by CMLS Holdings II.
F4 The shares reflected as beneficially owned by Casdin Partners Master Fund, L.P. in the table above are owned directly by Casdin Partners Master Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, L.P., (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
F5 The shares held by Casdin Private Growth Equity Fund, L.P. may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Private Growth Equity GP, LLC, the general partner of Casdin Private Growth Equity Fund, L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Private Growth Equity GP, LLC.
F6 The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin FO1, (ii) Casdin Partners GP, LLC, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

Remarks:

The Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.